2. Academic Validation
  3. Linoleic acid derivatives target miR-361-3p/BTG2 to confer anticancer effects in acute myeloid leukemia

Linoleic acid derivatives target miR-361-3p/BTG2 to confer anticancer effects in acute myeloid leukemia

  • J Biochem Mol Toxicol. 2023 Nov;37(11):e23481. doi: 10.1002/jbt.23481.
Shili Liu 1 2,  Huijuan Xu 3,  Zhen Li 1
Affiliations

Affiliations

  • 1 Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
  • 2 Clinical Laboratory, Suizhou Central Hospital, Suizhou, Hubei Province, People's Republic of China.
  • 3 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
PMID: 37497988 DOI: 10.1002/jbt.23481
Abstract

Acute myeloid leukemia (AML) is a deadly hematologic malignancy. In this study, miR-361-3p and BTG2 gene expression in AML blood and healthy specimens were analyzed using quantitative real-time reverse transcription polymerase chain reaction. A significant negative correlation between miR-361-3p and BTG2 was observed. The cell viability and Apoptosis were measured by CCK-8 assay, EdU incorporation assay and flow cytometry. A dual-luciferase reporter gene assay was performed to confirm the binding sequence between miR-361-3p and BTG2 messenger RNA 3'-untranslated region. 9s-Hydroxyoctadecadienoic acid (9s-HODE), a major active derivative of linoleic acid, reduced the viability and induced cell Apoptosis of HL-60 cells. Furthermore, the miR-361-3p mimics and siBTG2 reversed the above effects of 9s-HODE. 9s-HODE exerted an anti-AML effect through, at least partly, regulating the miR-361-3p/BTG2 axis.

Keywords

9s-Hydroxyoctadecadienoic acid; BTG2; acute myeloid leukemia; miR-361-3p.

Figures
Products